Ketone Body Metabolism and Sodium Glucose Cotransporter 2 Inhibitor Response in Heart Failure With Ischemic Cause: A Precision Medicine Approach Using Metabolomics Integration With Global Burden of Disease Population Data Across Diverse Genetic Backgrounds
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.048427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Qiang Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Jiangbin Hospital of Guangxi Zhuang Autonomous Region Nanning Guangxi China. Hauptthemen laut MEDLINE: Heart Failure, Metabolomics, Ketone Bodies, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure with ischemic cause is associated with substantial cardiovascular mortality. SGLT2 (sodium glucose cotransporter 2) inhibitors demonstrate cardiovascular benefits, but interindividual response variability remains poorly understood. We investigated the relationship between baseline ketone body metabolism and SGLT2 inhibitor response in heart failure with ischemic cause across diverse genetic backgrounds.
Methods
We analyzed metabolomics data from 3847 patients with heart failure with ischemic cause across 23 countries (2020–2024). Ketone body metabolites (β‐hydroxybutyrate, acetoacetate, acetone) were quantified by liquid chromatography‐mass spectrometry. SGLT2 inhibitor response was assessed via a composite end point including cardiovascular mortality, heart failure hospitalization, and kidney function decline. Analyses included multivariate Cox regression, machine learning (Random Forest, Extreme Gradient Boosting), and Mendelian randomization, integrating Global Burden of Disease 2021 data across 5 genetic ancestry groups.
Results
Baseline β‐hydroxybutyrate inversely correlated with SGLT2 inhibitor outcomes (r=−0.67, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology Jiangbin Hospital of Guangxi Zhuang Autonomous Region Nanning Guangxi China.
- Department of Cardiology The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang China.
- Senior Department of Cardiology Chinese PLA General Hospital Beijing China.
- Department of Geriatrics The Second Affiliated Hospital of Guangxi Medical University Nanning Guangxi China.
ORCID-Profile: Qiang Su, Wan-Zhong Huang, Chen-Kai Hu, Yuan Huang, Li-Rong Mo, Qiang Wu, Ying Huang
Zitieren
APA
Su, Q., Huang, W. Z., Hu, C. K., Huang, Y., Mo, L. R., Wu, Q., & Huang, Y. (2026). Ketone Body Metabolism and Sodium Glucose Cotransporter 2 Inhibitor Response in Heart Failure With Ischemic Cause: A Precision Medicine Approach Using Metabolomics Integration With Global Burden of Disease Population Data Across Diverse Genetic Backgrounds. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.048427
Vancouver
Su Q, Huang WZ, Hu CK, Huang Y, Mo LR, Wu Q, et al. Ketone Body Metabolism and Sodium Glucose Cotransporter 2 Inhibitor Response in Heart Failure With Ischemic Cause: A Precision Medicine Approach Using Metabolomics Integration With Global Burden of Disease Population Data Across Diverse Genetic Backgrounds. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.048427
BibTeX
@article{Su2026,
author = {Su, Qiang and Huang, Wan-Zhong and Hu, Chen-Kai and Huang, Yuan and Mo, Li-Rong and Wu, Qiang and Huang, Ying},
title = {Ketone Body Metabolism and Sodium Glucose Cotransporter 2 Inhibitor Response in Heart Failure With Ischemic Cause: A Precision Medicine Approach Using Metabolomics Integration With Global Burden of Disease Population Data Across Diverse Genetic Backgrounds},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.048427}
}
EUVIMED